Top Markets
#1 Zora Zora +31.42%
#2 SSV Network SSV Network +23.75%
#3 Arowana Arowana +23.56%
#4 Pieverse Pieverse +23.14%
#5 Fabric Protocol Fabric Protocol +22.66%
#6 EXOD EXOD +22.08%
#7 Backpack Backpack +22.06%
#8 The Black Bull The Black Bull +21.96%
#9 GALA GALA +21.77%
#10 Velvet Velvet +21.75%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Promore Pharma AB (publ) Promore Pharma AB (publ)

Promore Pharma AB (publ)

PROMO
Rank in Stocks #25502
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to... Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
Share Price
$1.34
Last synced: 2024-02-14
Market Cap
$48.96M
Change (1 day)
-12.94%
Change (1 year)
0.00%
Country
SE
Trade Promore Pharma AB (publ) (PROMO)

Category

Healthcare
P/E ratio for Promore Pharma AB (publ) (PROMO)
P/E ratio as of 2026 TTM: 0
According to Promore Pharma AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Promore Pharma AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.